ALIGOS THERAPEUTICS INC (ALGS) Fundamental Analysis & Valuation

NASDAQ:ALGS • US01626L2043

Current stock price

6.555 USD
-0.11 (-1.58%)
Last:

This ALGS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. ALGS Profitability Analysis

1.1 Basic Checks

  • In the past year ALGS has reported negative net income.
  • ALGS had a negative operating cash flow in the past year.
  • ALGS had negative earnings in each of the past 5 years.
  • In the past 5 years ALGS always reported negative operating cash flow.
ALGS Yearly Net Income VS EBIT VS OCF VS FCFALGS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 -20M -40M -60M -80M -100M

1.2 Ratios

  • ALGS has a Return On Assets of -27.33%. This is in the better half of the industry: ALGS outperforms 68.86% of its industry peers.
  • The Return On Equity of ALGS (-45.18%) is better than 66.73% of its industry peers.
Industry RankSector Rank
ROA -27.33%
ROE -45.18%
ROIC N/A
ROA(3y)-90.79%
ROA(5y)-78.47%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALGS Yearly ROA, ROE, ROICALGS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 2025 0 200 400

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for ALGS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALGS Yearly Profit, Operating, Gross MarginsALGS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 2025 -1K -2K -3K -4K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. ALGS Health Analysis

2.1 Basic Checks

  • ALGS does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • ALGS has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for ALGS has been reduced compared to 5 years ago.
  • The debt/assets ratio for ALGS has been reduced compared to a year ago.
ALGS Yearly Shares OutstandingALGS Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M
ALGS Yearly Total Debt VS Total AssetsALGS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M

2.2 Solvency

  • Based on the Altman-Z score of -11.87, we must say that ALGS is in the distress zone and has some risk of bankruptcy.
  • ALGS has a worse Altman-Z score (-11.87) than 76.40% of its industry peers.
  • ALGS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -11.87
ROIC/WACCN/A
WACC9.37%
ALGS Yearly LT Debt VS Equity VS FCFALGS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M

2.3 Liquidity

  • ALGS has a Current Ratio of 3.90. This indicates that ALGS is financially healthy and has no problem in meeting its short term obligations.
  • With a Current ratio value of 3.90, ALGS perfoms like the industry average, outperforming 46.81% of the companies in the same industry.
  • ALGS has a Quick Ratio of 3.90. This indicates that ALGS is financially healthy and has no problem in meeting its short term obligations.
  • ALGS has a Quick ratio (3.90) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.9
Quick Ratio 3.9
ALGS Yearly Current Assets VS Current LiabilitesALGS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. ALGS Growth Analysis

3.1 Past

  • ALGS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 23.10%, which is quite impressive.
  • ALGS shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -44.59%.
  • The Revenue for ALGS have been decreasing by -46.04% on average. This is quite bad
EPS 1Y (TTM)23.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.82%
Revenue 1Y (TTM)-44.59%
Revenue growth 3Y-46.04%
Revenue growth 5YN/A
Sales Q2Q%-73.13%

3.2 Future

  • ALGS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 27.13% yearly.
  • Based on estimates for the next years, ALGS will show a very strong growth in Revenue. The Revenue will grow by 165.30% on average per year.
EPS Next Y16.67%
EPS Next 2Y12.93%
EPS Next 3Y23.56%
EPS Next 5Y27.13%
Revenue Next Year-11.7%
Revenue Next 2Y-1.94%
Revenue Next 3Y144.19%
Revenue Next 5Y165.3%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ALGS Yearly Revenue VS EstimatesALGS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M 1B
ALGS Yearly EPS VS EstimatesALGS Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -50 -100

More info and screens

Find the best growth stocksShow best growing peers

1

4. ALGS Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ALGS. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ALGS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALGS Price Earnings VS Forward Price EarningsALGS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALGS Per share dataALGS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 -10

4.3 Compensation for Growth

  • A more expensive valuation may be justified as ALGS's earnings are expected to grow with 23.56% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y12.93%
EPS Next 3Y23.56%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ALGS Dividend Analysis

5.1 Amount

  • No dividends for ALGS!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ALGS Fundamentals: All Metrics, Ratios and Statistics

ALIGOS THERAPEUTICS INC

NASDAQ:ALGS (3/30/2026, 10:34:37 AM)

6.555

-0.11 (-1.58%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-05
Earnings (Next)05-04
Inst Owners52.5%
Inst Owner Change-4.59%
Ins Owners2.13%
Ins Owner Change0%
Market Cap40.58M
Revenue(TTM)2.19M
Net Income(TTM)-24.19M
Analysts83.64
Price Target39.27 (499.08%)
Short Float %6.04%
Short Ratio4.94
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-28.99%
Min EPS beat(2)-56.86%
Max EPS beat(2)-1.11%
EPS beat(4)2
Avg EPS beat(4)1.15%
Min EPS beat(4)-56.86%
Max EPS beat(4)36.53%
EPS beat(8)3
Avg EPS beat(8)4.7%
EPS beat(12)6
Avg EPS beat(12)6.73%
EPS beat(16)8
Avg EPS beat(16)7.39%
Revenue beat(2)1
Avg Revenue beat(2)-17%
Min Revenue beat(2)-79.29%
Max Revenue beat(2)45.29%
Revenue beat(4)2
Avg Revenue beat(4)18.95%
Min Revenue beat(4)-79.29%
Max Revenue beat(4)118.33%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-43.55%
PT rev (3m)-52.02%
EPS NQ rev (1m)1.68%
EPS NQ rev (3m)-11.28%
EPS NY rev (1m)0%
EPS NY rev (3m)0.74%
Revenue NQ rev (1m)50%
Revenue NQ rev (3m)50%
Revenue NY rev (1m)5.86%
Revenue NY rev (3m)5.86%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 18.56
P/FCF N/A
P/OCF N/A
P/B 0.76
P/tB 0.76
EV/EBITDA N/A
EPS(TTM)-8.59
EYN/A
EPS(NY)-7.16
Fwd EYN/A
FCF(TTM)-13.4
FCFYN/A
OCF(TTM)-13.33
OCFYN/A
SpS0.35
BVpS8.65
TBVpS8.65
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -27.33%
ROE -45.18%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-90.79%
ROA(5y)-78.47%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 46.99%
Cap/Sales 19.99%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.9
Quick Ratio 3.9
Altman-Z -11.87
F-Score4
WACC9.37%
ROIC/WACCN/A
Cap/Depr(3y)20.29%
Cap/Depr(5y)26.21%
Cap/Sales(3y)7.8%
Cap/Sales(5y)10.12%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)23.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.82%
EPS Next Y16.67%
EPS Next 2Y12.93%
EPS Next 3Y23.56%
EPS Next 5Y27.13%
Revenue 1Y (TTM)-44.59%
Revenue growth 3Y-46.04%
Revenue growth 5YN/A
Sales Q2Q%-73.13%
Revenue Next Year-11.7%
Revenue Next 2Y-1.94%
Revenue Next 3Y144.19%
Revenue Next 5Y165.3%
EBIT growth 1Y-3.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-45.09%
EBIT Next 3Y-18.41%
EBIT Next 5Y-0.26%
FCF growth 1Y-2.56%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-2.18%
OCF growth 3YN/A
OCF growth 5YN/A

ALIGOS THERAPEUTICS INC / ALGS Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for ALIGOS THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 3 / 10 to ALGS.


What is the valuation status of ALIGOS THERAPEUTICS INC (ALGS) stock?

ChartMill assigns a valuation rating of 1 / 10 to ALIGOS THERAPEUTICS INC (ALGS). This can be considered as Overvalued.


How profitable is ALIGOS THERAPEUTICS INC (ALGS) stock?

ALIGOS THERAPEUTICS INC (ALGS) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for ALGS stock?

The Earnings per Share (EPS) of ALIGOS THERAPEUTICS INC (ALGS) is expected to grow by 16.67% in the next year.